On 6 January 2021 orphan designation EU/3/20/2395 was granted by the European Commission to Morrison & Foerster, Belgium, for celecoxib, ciprofloxacin (also known as PrimeC) for the treatment of amyotrophic lateral sclerosis.
Treatment of amyotrophic lateral sclerosis
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
|September 2023||The sponsorship was transferred from Ferenc Tracik, Germany to NeuroSense EU GmbH, Germany.|
|June 2022||The sponsorship was transferred from Morrison & Foerster, Belgium to Ferenc Tracik, Germany.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: